2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - Hall B
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Monoclonal Antibody Therapy, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, MPN, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

243 Safety, tolerability, and efficacy of elenestinib in indolent systemic mastocytosis: Longer-term, open-label data from the ongoing Phase 2/3 HARBOR trial

Jens Panse, MD, Ivan Alvarez-Twose, MD, PhD2, Olivier Hermine, MD, PhD3, Tse-Chieh Teh, MD4, Clive Grattan, MD, FRCP5, William Shomali, MD6, Laurence Bouillet, MD, PhD7, Renata Cabral, MD8, Robert Bird, MBBS, MRCP9, Chiara Elena, MD10, Elizabeth A. Griffiths, MD11, Gandhi Damaj, MD, PhD12, Joseph Jurcic, MD13, Marie-Pierre Gourin, MD14, Pankit Vachhani, MD15, Philippe Schafhausen, MD16, Hussein Ali Abbas, MD, PhD17, Tracy George, MD18, Sam Tamulevich19, Kevin He20, Javier Munoz-Gonzalez, PhD21, Robyn Scherber, MD, MPH22, Tsewang Tashi, MD23
1 Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Aachen, Germany, Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital Aachen, Medical Faculty, RWTH Aachen University, Aachen, Germany
2 Health Research Institute of Castilla-La Mancha (IDISCAM), Toledo, Spain, Institute of Mastocytosis Studies of Castilla-La Mancha (CLMast), Virgen del Valle Hospital, Toledo, Spain
3 Hôpital Necker, Paris, France
4 Department of Clinical Hematology, The Alfred Hospital, Melbourne, Victoria, Australia
5 St John's Institute of Dermatology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom
6 Department of Medicine/Division of Hematology, Stanford University School of Medicine, Stanford, California, United States
7 Internal Medicine Department, CHU Grenoble Alpes, Grenoble, France
8 Unidade Local de Saude Santo António and ICBAS-School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal Continental, Portugal
9 Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
10 Department of Molecular Medicine & Department of Hematology and Oncology, The University of Pavia, Pavia, Italy
11 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
12 Hematology Institute, CHU de Caen, Caen, France
13 Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York, New York, United States
14 Centre Hospitalier Universitaire de Limoges Radiologie, Limoges, France
15 Department of Hematology/Oncology, and Bone Marrow Transplantation with Section of Pneumology, University of Alabama at Birmingham, Birmingham, Alabama, United States
16 University Medical Center Hamburg, Eppendorf, Hamburg, Germany
17 Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 ARUP Laboratories, University of Utah School of Medicine, Salt Lake City, Utah, United States, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
19 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
20 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
21 Blueprint Medicines (Switzerland) GmbH, Zug, Switzerland
22 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
23 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States

Introduction:

Systemic mastocytosis (SM) is a rare clonal mast cell disease, primarily driven by the KIT D816V mutation in ~95% of adult cases. In the most common form, indolent SM (ISM), accumulation and abnormal activation of mast cells can lead to chronic, debilitating gastrointestinal, neurocognitive, and skin symptoms, life-threatening anaphylaxis, and bone manifestations, all of which negatively impact quality of life. Symptom-directed therapies (SDTs) are commonly used in patients with ISM but do not target the underlying disease driver.

Elenestinib is a next-generation, potent, and highly selective KIT D816V inhibitor with limited central nervous system penetration and minimal off-target wild-type KIT inhibition. It is currently being evaluated in HARBOR (NCT04910685). In the dose-finding portion of the trial (Part 1), elenestinib (across 25-, 50-, and 100-mg once daily [QD] dose levels + SDT) was well tolerated, improved disease-related symptoms, and reduced multiple biomarkers of mast cell burden in patients with ISM. Parallel, open-label pharmacokinetic (PK) groups also received 50-, 75-, and 100-mg QD doses + SDT to further characterize the benefit-risk profile. Based on these findings, elenestinib 75 mg QD + SDT was selected as the recommended dose for HARBOR Part 2 (randomized, double-blind, placebo-controlled) and Part 3 (long-term extension) to allow for long-term tolerability with the end goal of disease modification. Patients in Part 3 have the option to dose-escalate to elenestinib 100 mg QD + SDT to allow for dosing flexibility.

Here, we present longer-term efficacy (~2 years) and all available safety data (~3 years) among patients receiving elenestinib 75 mg QD + SDT in the open-label PK group of HARBOR.

Methods:

For inclusion in the elenestinib 75 mg QD + SDT PK group of HARBOR, patients had to be ≥18 years old, have a centrally confirmed diagnosis of ISM, a minimum 14-day average total symptom score (TSS) during the eligibility period ≥20 (as measured by the ISM-Symptom Assessment Form [ISM-SAF; ©2018 Blueprint Medicines Corporation]), and evidence of uncontrolled disease (defined as a single ISM-SAF domain score ≥7). Endpoints of interest in the current analysis were changes in the proportion of patients with mild, moderate, and severe TSS, as well as safety and tolerability.

Results:

Overall, 36 patients were treated with elenestinib 75 mg QD + SDT by February 10, 2026. Median (range) age was 52.5 (23–70) years, and most patients (n=27 [75%]) were female. Baseline median (range) ISM-SAF TSS was 46.71 (17.1–96.6), and median (range) KIT D816V variant allele fraction was 0.08 (undetectable–39.41; limit of detection: <0.022%). Median (range) serum tryptase was 28.5 (9.1–213.6), and 13 (36.1%) patients had tryptase <20 ng/mL.

At baseline, most patients presented with severe symptoms of ISM (n=20/34 [58.8%]; ISM-SAF TSS ≥42), while the remainder had moderate (n=7/34 [20.6%]; ISM-SAF TSS ≥28 to <42) or mild (n=7/34 [20.6%]; ISM-SAF TSS <28) symptoms. By the data cut off, all patients had efficacy data at ~2 years; 67% of patients (n=24) achieved symptom control as defined by attaining a mild TSS score (<28), and 33% of patients (n=12) continued to have TSS ≥28.

Safety data are presented after a median (SD) treatment duration of 149.8 weeks (~3 years). Treatment with elenestinib 75 mg QD + SDT was well tolerated, in line with the previously reported dose-finding portion of the trial. Most treatment-related adverse events (TRAEs) were Grades 1–2, and 2 (5.6%) patients experienced Grade ≥3 TRAEs. All events of nausea, the most frequently reported TRAE, were Grade 1 or 2.

Conclusion:

Multi-year treatment with elenestinib 75 mg QD + SDT provided deep and sustained symptom control with low rates of off-target toxicities, supporting selection as the recommended dose for HARBOR Parts 2 and 3. HARBOR is actively enrolling at multiple sites.

Jens Panse, MD: BMS - Honoraria; MSD - Honoraria; Blueprint Medicines Corporation, a wholly-owned subsidiary of Sanofi - Honoraria; AstraZeneca - Honoraria; Sobi - Honoraria; F. Hoffmann-La Roche - Honoraria; Grünenthal - Honoraria; Apellis - Honoraria; Alexion - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Chugai - Consultancy (Includes expert testimony); Boehringer Ingelheim - Consultancy (Includes expert testimony)